Current Medicinal Chemistry Journal Impact Factor & Information

Publisher: Bentham Science Publishers

Journal description

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each bi-weekly issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Current impact factor: 3.85

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 3.853
2013 Impact Factor 3.715
2012 Impact Factor 4.07
2011 Impact Factor 4.859
2010 Impact Factor 4.63
2009 Impact Factor 4.708
2008 Impact Factor 4.823
2007 Impact Factor 4.944
2006 Impact Factor 5.207
2005 Impact Factor 4.904
2004 Impact Factor 4.382
2003 Impact Factor 4.409
2002 Impact Factor 4.966
2001 Impact Factor 5.76
2000 Impact Factor 4.909
1999 Impact Factor 3
1998 Impact Factor 1.522
1997 Impact Factor 2.269

Impact factor over time

Impact factor

Additional details

5-year impact 4.12
Cited half-life 5.80
Immediacy index 0.85
Eigenfactor 0.03
Article influence 1.00
Website Current Medicinal Chemistry website
Other titles Current medicinal chemistry (Online)
ISSN 1875-533X
OCLC 55201153
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Bentham Science Publishers

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Author's pre-print on author's personal website, institutional repository and open access repository
    • Author's post-print on author's personal website, institutional repository, open access repository, PubMed Central and arXiv
    • Non-Commercial
    • Published source must be acknowledged
    • Must link to journal homepage with DOI
    • Publisher's version/PDF cannot be used
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Carriership of coagulation factor V Leiden (FVL) is by far the most common thrombophilia in Western populations. FVL is caused by a single point mutation in the gene coding for coagulation factor V (FV) causing a lifelong procoagulatory state with an increased risk of venous thromboembolism (VTE) which might be fatal. It is believed that the mutation occurred in one person 21,000 years ago and today 3% to 15% of the Western populations are carriers. A potentially dangerous mutation such as FVL ought to be rare and should have been reduced, if not eradicated, by selection during the course of human evolution. Thus, FVL must confer the carriers with an evolutionary advantage in order to be so prevalent. Lower risk of profuse bleeding and increased fecundity might give carriers an advantage. In this paper we give an updated short background and discuss possible evolutionary advantages and disadvantages.
    Current Medicinal Chemistry 10/2015; 22(999). DOI:10.2174/0929867322666151001121707
  • [Show abstract] [Hide abstract]
    ABSTRACT: Disturbance in the functioning of the gastrointestinal (GI) tract can critically affect the health and even the life of the whole organism. Several factors, both exo- and endogenous may contribute to the dysregulation of homeostasis in the digestive system, including genetic background, ingestion of highly processed food, exposition to environmental pollution or chronic stress, and changes in gut microflora, to name just a few. An important number of these factors rely on metals, which often play a dual, stimulatory and inhibitory role in crucial physiological processes. In this paper, we focus on the structures incorporating silver, copper and other metals as future drugs against GI diseases. We critically review available literature for their effectiveness and potential application, and discuss clinical relevance of these findings.
    Current Medicinal Chemistry 10/2015; 22(999). DOI:10.2174/0929867322666151001121439
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease (CVD) is a leading cause of death for both women and men. Common traditional risk factors for CVD, such as hypercholesterolemia, hypertension and smoking have a high prevalence in women and in some cases a greater health impact compared with men. Nevertheless, risk factors are treated less often and less aggressively in women than in men, partly due to decreased awareness on the part of public health opinion makers, patients and physicians. About seventy five percent of all coronary heart disease deaths among women could be avoided if CVD risk factors like hypercholesterolemia, hypertension and smoking are adequately treated. This narrative review discusses the treatment of the 4 CVD risk factors, namely hypercholesterolemia, hypertension, smoking and diabetes. These risk factors were examined in the Framingham Heart study and years later they were found in the INTERHEART study to be the 4 most important risk factors for the development of CVD.
    Current Medicinal Chemistry 10/2015; 22(999). DOI:10.2174/0929867322666151001122213
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are significant differences in coronary heart disease (CHD) in women whenever a comparison is made to men and these carry over to revascularization procedures including percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. The coronary arteries of women are smaller, which presents additional challenges for PCI and CABG procedures. Unique atypical symptomatology in response to acute coronary syndrome (ACS) in women can confound diagnosis, women notoriously delay seeking medical help for ACS, and physicians and other caregivers have had a tendency to minimize the significance of these symptoms, contributing further to a delay in necessary care. There also appears to be an increased association of inflammation and CHD in women. The younger the female patient with CHD, the higher the mortality and that mortality clearly exceeds that of comparable male patients. For cardiovascular (CV) risk prevention in women, statins have had controversy associated with their use but overall, the proof of beneficial outcomes results from statins is also valid in women. An increased rate of adverse outcomes has been reported in women after PCI and CABG surgery. These worse clinical outcomes have persisted in contemporary years but lessened due to advancement in invasive techniques. Nevertheless, PCI that could improve clinical outcomes in women who have high-risk ACS is, unfortunately, performed on a less frequent basis and, in addition, there are greater delays involving women as compared to men. With increased clinical comorbidity associated with complex CHD in women, a lower anatomical SYNTAX score (from: SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery [SYNTAX] trial) appears necessary in order for women to achieve a similar long-term mortality benefit from CABG surgery as compared to PCI.
    Current Medicinal Chemistry 10/2015; 22(999). DOI:10.2174/0929867322666151001122007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oxaliplatin is one of the most widely used anticancer drugs representing the cornerstone of the treatment of colorectal cancer. Yet a number of side effects, including oxaliplatin-induced peripheral neurotoxicity (OIPN) which represents a dose-limiting side effect in the clinical use of oxaliplatin limit its use and a better understanding of its pathogenesis would offer a great opportunity to improve the "quality of survival" of cancer patients. So far, no treatment able to prevent or limit OIPN has been approved, and one of the reasons for this unmet clinical need is the incomplete knowledge of its pathogenesis preventing the development of rationale-based pharmacological interventions. Preclinical and clinical evidence raised the hypothesis that intracellular calcium-related events might play an important role in the onset of OIPN. Yet, the results of mechanistic pre-clinical studies appear inconsistent and, therefore, their relevance in neuroprotective drugs design is still uncertain. Indeed, it is at present unclear whether aberrant calcium signalling is the key pathogenetic moment or whether it just constitutes the mediator of the clinical phenotype. This review will summarize the preclinical results involving calcium-related events and OIPN with the aim to provide an updated overview of the available evidence and highlight the most promising strategies to design effective neuroprotective drugs. In particular, we will focus on the pre-clinical evidence suggesting that TRPV1, TRPM8 or TRPA1 might be involved, as these appear particularly amenable to pharmacological modulation.
    Current Medicinal Chemistry 10/2015; 22(999). DOI:10.2174/0929867322666151001121302
  • [Show abstract] [Hide abstract]
    ABSTRACT: A key barrier to the development of gene therapy remains the lack of safe, efficient and easily controllable vehicles for gene delivery. The fundamental problems associated with the viral vehicles, e.g. lack of specificity and immunogenic potential, have driven the development of non-viral systems of gene delivery. In the last decade, studies on p53 gene replacement therapy have dominated the literature. Although clinical trials of p53 gene therapy have achieved limited success, it remains the only tumor suppressor gene to be evaluated formally in clinical trials for cancer treatment, with increasing focus on delivery using non-viral systems. In this article, we particularly review current investigations on p53 gene delivery using non-viral methods, including both physical and chemical approaches, with an emphasis on the latter. The existing opportunities and challenges for successful p53 cancer gene therapy are also discussed.
    Current Medicinal Chemistry 10/2015; 22(999). DOI:10.2174/0929867322666151001121601
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multimodal imaging agents were first introduced a decade ago and consist of a targeting moiety that is dual-labeled with radioactive and fluorescent contrast. These compounds allow whole-body and intraoperative imaging to be performed through administration of a single agent and provide complementary diagnostic information that can be used to guide tumor resection. Since their initial evaluation, interest in dual-labeled agents has continued to grow and their design has subsequently evolved alongside the development of novel chelating agents, improved fluorophores, and highly selective coupling techniques for bioconjugate formation. In this review, will discuss how changes in the labeling components and schemes for multimodal agent development have impacted imaging performance and will focus on antibody- and peptide-based agents as models for dual labeling. We will also describe the growing role of modular dual labeling strategies as well as direct labeling methods using radiohalogens.
    Current Medicinal Chemistry 09/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is the process of formation of new capillaries from preexisting blood vessels. Angiogenesis is involved in normal physiological processes, and plays an important role in tumor invasion and development of metastases. Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis. VEGF is a mitogen for vascular endothelial cells and stimulates their proliferation. By inhibiting the biological activity of VEGF and then signal cascades with neutralizing VEGF antibodies and signal inhibitors may negatively regulate the growth and metastasis. Anti-angiogenesis therapy is less toxic than chemotherapy. Angiogenesis is a multistep process and multifactorial, and therefore, can be blocked at different levels. In this review article, the authors present the synthesis of novel inhibitors of angiogenesis, together with the results of biological tests in vitro, and in some cases, state trials.
    Current Medicinal Chemistry 09/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Natural products drug discovery has allowed the identification of many biologically active compounds from plants, microbial species, and marine organisms. A significant number of these compounds are currently used as drugs in therapeutic protocols, while other naturally occurring chemical entities gave suggestions for designing nonnatural-product-derived drugs or have been modified in their structure to have semi-synthetic analogues. In the last decade, experimental evidence that correlated the aberrant activation of the Hedgehog (Hh) signaling pathway with many types of cancer, prompted the researchers to check natural compounds for their ability to modulate this signaling cascade. As a result, many compounds from natural sources showed inhibitory activity toward one or more of the Hh signaling pathway components, such as Smoothened (Smo) and the downstream effectors Gli. On the other hand, only a few natural compounds were able to stimulate the same pathway. This review reports a survey of the compounds extracted from natural sources (especially plants) that showed activity in inhibiting or stimulating the Hh signaling machinery by interfering with its components.
    Current Medicinal Chemistry 09/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regardless of significant improvement in the area of anti-HBV therapy, resistance and cross-resistance against available therapeutic agents are the major consideration in drug discovery of new agents. The present study is to obtain the insight of the molecular basis of drug resistance conferred by the B and C domain mutations of HBV-polymerase on the binding affinity of four anti-HBV agents [Adefovir (ADV), Tenofovir (TNF), Entecavir (ETV) & 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA)]. In this regard, homology modeled structure of HBV polymerase was used for minimization, conformational search and Glide XP docking followed by binding energy calculation on wild-type as well as on mutant HBV-polymerases (N236T, L180M+M204V+S202G & A194T). Our studies suggest a significant correlation between the fold resistances and the binding affinity of anti-HBV nucleosides. The domain B residue, L180 is indirectly associated with other active-site hydrophobic residues such as A87, F88 and M204, whereas the domain C residue, M204 is closely associated with sugar/pseudosugar ring positioning in the active site. These hydrophobic residues can directly influence the interaction of the incoming nucleoside triphosphates and change the binding efficacy. The carbohydrate ring part of natural substrate dATP, dGTP, FMCA and ETV, are occupied in similar passion in the grooves of HBV polymerase active site. The exocyclic double bond of Entecavir and FMCA occupies in the backside hydrophobic pocket (made by residues A87, F88, L180and M204), which enhances the overall binding affinity. Additional hydrogen bonding interaction of 2'-fluorine of FMCA with R41 residue of polymerase promotes a positive binding in wild-type as well as in ADVr, ETVr and TNFr with respect to that of entecavir.
    Current Medicinal Chemistry 09/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gender differences have been reported for traditional vascular risk factors such as smoking, obesity, diabetes, hypertension, dyslipidemia, age and family history of premature coronary heart disease. The prevalence, severity, associations and response to treatment of several emerging cardiovascular disease (CVD) risk factors may also differ between men and women. Such CVD risk factors include certain inflammatory and hemostatic markers, endothelial dysfunction, homocysteine, lipid disorders, microalbuminuria/proteinuria, coronary artery calcium score, arterial stiffness, periodontitis, inflammatory bowel syndrome, obstructive sleep apnea, impaired glucose metabolism, metabolic syndrome and non-alcoholic fatty liver disease. Further larger prospective studies are needed to establish these relationships. Hormone replacement therapy may also affect vascular risk. These data should be taken into consideration when assessing and treating CVD risk in women.
    Current Medicinal Chemistry 09/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerotic Coronary heart disease (CHD) and non-atherosclerotic CHD in individuals less than 50 years of age is considered a "men's case". Undoubtedly, premenopausal women develop atherosclerotic/non-atherosclerotic CHD relatively rarely compared with men. This is attributed mostly to the cardioprotective role of estrogens (mainly estradiol). Nevertheless, there are predisposing conditions, which also make young women vulnerable to develop atherosclerotic/non-atherosclerotic CHD. Women who have classical cardiovascular (CV) risk factors, such as hypertension, diabetes mellitus, smoking, obesity, dyslipidaemia, are more likely to develop cardiac events, even at a young age. Moreover, there are also other conditions that cause acute coronary syndromes, even in the absence of coronary atheromatic plaques such as myocardial bridge, coronary artery dissection, coronary artery spasm, coronary artery embolism and congenital anomalies of coronary arteries. Also, autoimmune diseases, some of which are more prevalent in women can cause atherosclerotic/non-atherosclerotic CHD. In this narrative review we have summarized some of the causes that predispose young women to develop atherosclerotic/non-atherosclerotic CHD.
    Current Medicinal Chemistry 09/2015;
  • Current Medicinal Chemistry 08/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The hedgehog (Hh) pathway is a developmental signaling pathway that is essential to the proper embryonic development of many vertebrate systems. Dysregulation of Hh signaling has been implicated as a causative factor in the development and progression of several forms of human cancer. As such, the development of small molecule inhibitors of Hh signaling as potential anti-cancer chemotherapeutics has been a major area of research interest in both academics and industry over the past ten years. Through these efforts, synthetic small molecules that target multiple components of the Hh pathway have been identified and advanced to preclinical or clinical development. The goal of this review is to provide an update on the current status of several synthetic small molecule Hh pathway inhibitors and explore the potential of several recently disclosed inhibitory scaffolds.
    Current Medicinal Chemistry 08/2015; 22(999). DOI:10.2174/0929867322666150827093904
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell-to-cell signaling molecules such as the Wnt proteins that directly influence the expression of cell-type specific transcriptional programs are essential for tissue generation in metazoans. The mechanisms supporting cellular responses to these molecules represent potential points of intervention for directing cell fate outcomes in therapeutic contexts. Small molecules that modulate Wnt-mediated cellular responses have proven to be powerful probes for Wnt protein function in diverse biological settings including cancer, development, and regeneration. Whereas efforts to develop these chemicals as therapeutic agents have dominated conversation, the unprecedented modes-of-action associated with these molecules and their implications for drug development deserve greater examination. In this review, we will discuss how medicinal chemistry efforts focused on first in class small molecules targeting two Wnt pathway components - the polytopic Porcupine (Porcn) acyltransferase and the cytoplasmic Tankyrase (Tnks) poly-ADP-ribosylases - have contributed to our understanding of the druggable genome and expanded the armamentarium of chemicals that can be used to influence cell fate decision-making.
    Current Medicinal Chemistry 08/2015; 22(999). DOI:10.2174/0929867322666150827094015
  • [Show abstract] [Hide abstract]
    ABSTRACT: As a significant tumor feature, hypoxia can trigger cancer adaptive processes, induce malignant phenotype development, and promote drug resistance. Previous studies demonstrated that exosomes are critical during these procedures. Exosomes are small vesicles formed in vesicular bodies in the endosomal network. These small vesicles are mainly involved in the transport of bioactive molecules between cells. Exosomes are also involved in the mediation of some cellular communications depending on derived donor cells; thus, recipient cells undergo phenotypic changes. Furthermore, hypoxia can remarkably stimulate exosomal secretion; for instance, nucleic acids and proteins as transmission signals in exosomes in a tumor microenvironment are involved in various functions, such as inducing intratumoral heterogeneity, altering immunological responses, producing cancer-associated fibroblasts, and promoting angiogenesis and metastasis. Moreover, exosome contents resemble those of a donor cell; this finding indicates that exosomes may also be regarded as suitable biomarkers of hypoxia status. Therefore, exosomes can be used to facilitate diagnosis and prognosis with minimal invasive procedures. Further studies on exosomes in cancer may provide new therapeutic strategies.
    Current Medicinal Chemistry 08/2015; 22(999). DOI:10.2174/0929867322666150825163318
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gene therapy requires safe and effective vectors to deliver genes to their target site of action. Non-viral gene delivery systems have attracted growing attention due to their low toxicity, low immunogenicity and ease of production compared to viral vectors. Most non-viral gene delivery systems enter cells via endocytic pathways, and their escape from endosomes is therefore a crucial for successful transfection. Several reagents have been developed to promote endosomal escape, including peptides, polymers and lipids. Among these, endosome-disrupting peptides have been used in many studies, and have proven to be one of the most promising approaches to overcome endosomal entrapment and lysosomal degradation. This review provides an up-to-date summary of strategies for enhancing endosomal escape, with a focus on the modification of endosome-disrupting peptides to further increase the efficient delivery of oligonucleotides.
    Current Medicinal Chemistry 08/2015; 22(999). DOI:10.2174/0929867322666150825162941
  • [Show abstract] [Hide abstract]
    ABSTRACT: The bio-reversible protection of nucleoside diphosphates is summarized. The design, the hydrolysis behavior, and the antiviral activity of these prodrugs of NDPs are described. In contrast to earlier attempts, the DiPPro-approach [-(bis (acyloxybenzyl) nucleoside diphosphates)] successfully led to the delivery of the nucleoside diphosphates. It was proven [by hydrolysis studies in aqueous PBS buffer (pH 7.3), 20 % human plasma in PBS, RPMI-1640 culture medium, and CEM cell extracts] that the stability towards hydrolysis was dependent on the acyl moieties in the bis (acyloxybenzyl) unit as well as on the nucleoside analogue. Contrary to a high chemical and plasma stability, the compounds showed a very low half-life in CEM cell extracts, and efficiently released the nucleoside analogues diphosphates, e.g. of AZT, d4T and BVDU. Two types of cycloSal-NDP prodrugs were also initially studied but proved to be not useful as nucleoside diphosphate prodrugs. Finally the obtained results led to the development of non-symmetric nucleoside diphosphate prodrugs that selectively deliver the nucleoside diphosphate in cell extracts.
    Current Medicinal Chemistry 08/2015; 22(999). DOI:10.2174/0929867322666150825163119